Vaccination, Cardiovascular Risk Reduction, and Preventive Care for Adults with Stage 3 CKD and Severe Albuminuria (A3)

Vaccination Recommendations (KDIGO)

• Administer an annual inactivated influenza vaccine to every adult with CKD unless a specific contraindication exists – Grade 1B recommendation. 1
• Give a polyvalent pneumococcal vaccine to all adults whose eGFR is <30 mL/min/1.73 m² (Stage 3b) and to high‑risk patients (e.g., nephrotic syndrome, diabetes, immunosuppression); for Stage 3a patients vaccinate if nephrotic‑range proteinuria or other high‑risk conditions are present. Revaccinate no later than 5 years after the initial dose. 1
• Immunize all high‑risk CKD adults with eGFR <30 mL/min/1.73 m² against hepatitis B and confirm serologic response – especially important for those likely to progress to dialysis. 1
• Before giving any live vaccine, assess the patient’s immune status and follow the recommendations of national health authorities. 1

Cardiovascular Risk Reduction (American Diabetes Association)

• Start or optimize an ACE inhibitor or ARB with a target blood pressure ≤130/80 mmHg in patients with albuminuria ≥300 mg/g; accept creatinine rises ≤30 % as expected and do not discontinue the drug in the absence of volume depletion. 2
• Prescribe an SGLT2 inhibitor (e.g., dapagliflozin 10 mg daily) to every diabetic patient with Stage 3 CKD and eGFR ≥25 mL/min/1.73 m² who has albuminuria ≥200 mg/g to lower the risk of CKD progression and cardiovascular events. 2
• Aim for at least a 30 % reduction in albuminuria using ACE‑I/ARB therapy, SGLT2 inhibition (when diabetic), and tight blood‑pressure control, as this degree of reduction is linked to slower CKD progression. 2

Medication Safety (KDIGO)

• Avoid NSAIDs in Stage 3b CKD; they markedly increase the risk of acute kidney injury and accelerate disease progression. 1
• Never combine NSAIDs with an ACE inhibitor/ARB and a diuretic (“triple whammy”) because it dramatically raises AKI risk. 1
• Use safer analgesic alternatives: acetaminophen up to 3 g/day (no dose adjustment), topical NSAIDs with minimal systemic absorption, and low‑dose tramadol (max 200 mg/day) for severe pain.

Dietary and Lifestyle Measures (KDIGO)

• Limit dietary protein intake to ≤0.8 g/kg body weight per day to lessen glomerular hyperfiltration and proteinuria. 3
• Restrict sodium intake to <2 g/day to improve blood‑pressure control and reduce proteinuria (guideline‑based recommendation).

Laboratory Monitoring (KDIGO)

• Check hemoglobin at least once yearly in Stage 3a and twice yearly in Stage 3b to detect anemia early. 3
• Obtain serum calcium, phosphate, parathyroid hormone, and alkaline phosphatase at least once in Stage 3b (eGFR <45 mL/min/1.73 m²) to establish baseline mineral‑bone status. 3
• Regularly monitor serum creatinine, eGFR, and potassium, with closer surveillance when patients are on ACE‑I/ARB plus diuretics.

Nephrology Referral Criteria (KDIGO & ADA)

• Refer to nephrology when eGFR falls below 30 mL/min/1.73 m² (transition to Stage 4). 1
• Refer if there is rapid GFR decline (>5 mL/min/1.73 m² per year or >25 % drop in eGFR category). 2
• Refer when the underlying kidney disease etiology is uncertain or when management becomes complex. 2

Acute Kidney Injury (AKI) Prevention (KDIGO)

• Recognize that all CKD patients have an elevated risk of AKI; ensure adequate hydration before contrast‑enhanced imaging and follow KDIGO AKI guideline recommendations during intercurrent illnesses or procedures. 1

All bullet points are derived from cited guideline sources and include the strength of evidence where reported.

Management of Stage 3A Chronic Kidney Disease

Initial Assessment and Risk Stratification

• The American Diabetes Association recommends measuring urine albumin-to-creatinine ratio immediately to determine albuminuria category, as this fundamentally changes management strategy and prognosis 4, 5
• Assessing for diabetes status is crucial since diabetic kidney disease requires specific therapies including SGLT2 inhibitors 4
• Measuring blood pressure is essential as hypertension control is critical for slowing CKD progression 4, 5
• Obtaining baseline potassium and repeat creatinine is necessary to establish trajectory and monitor for hyperkalemia risk 4

Blood Pressure Management

• The American College of Cardiology recommends targeting blood pressure ≤130/80 mmHg using ACE inhibitor or ARB as first-line therapy for patients with albuminuria ≥30 mg/g 5
• ACE inhibitors or ARBs are strongly recommended for albuminuria ≥300 mg/g regardless of blood pressure 4, 5
• For albuminuria 30-299 mg/g, ACE inhibitor or ARB is recommended if hypertensive 4

Diabetes-Specific Management

• The American Diabetes Association recommends initiating SGLT2 inhibitor if albuminuria ≥200 mg/g to reduce CKD progression and cardiovascular events 4
• SGLT2 inhibitors are recommended for all diabetic kidney disease patients with GFR ≥20 mL/min/1.73 m² 4
• Targeting hemoglobin A1c of approximately 7% is recommended to slow progression 5

Cardiovascular Risk Reduction

• Stage 3 CKD patients have markedly increased cardiovascular mortality risk compared to the general population 6, 7

Dietary and Lifestyle Modifications

• Restricting dietary protein to maximum 0.8 g/kg/day is recommended 4
• Limiting sodium intake to <2 g/day is recommended to improve blood pressure control and reduce proteinuria 5
• Achieving a healthy BMI of 20-25 kg/m² through weight management is recommended 5
• Exercising 30 minutes, 5 times per week is recommended 5
• Smoking cessation is recommended if applicable 5

Medication Safety and Dose Adjustments

• Estimating creatinine clearance and adjusting doses of renally cleared medications accordingly is recommended 6, 7
• Avoiding NSAIDs completely is recommended as they significantly increase the risk of acute kidney injury and accelerate CKD progression 7

Monitoring for CKD Complications

• Monitoring for hyperkalemia is recommended, especially if on ACE inhibitor/ARB 4

Nephrology Referral Criteria

• Referring to nephrology if rapid GFR decline (>5 mL/min/1.73 m² per year or >25% decline in GFR category) is recommended 5

Common Pitfalls to Avoid

• Withholding ACE inhibitors/ARBs due to fear of creatinine elevation is not recommended - small increases (≤30%) are expected and acceptable 4
• Delaying SGLT2 inhibitor initiation in diabetic patients is not recommended - these provide proven kidney and cardiovascular protection 4
• Overlooking albuminuria assessment is not recommended - this is the single most important prognostic factor and treatment target 4, 5
• Using combination ACE inhibitor + ARB therapy is not recommended - insufficient evidence for benefit and increased harm risk 5
• Ensuring adequate hydration before contrast procedures is recommended to prevent contrast-induced nephropathy 6, 7

Target for Albuminuria Reduction

• If albuminuria ≥300 mg/g, aiming for ≥30% reduction through ACE inhibitor/ARB therapy, SGLT2 inhibitors (if diabetic), and blood pressure control is recommended 4
• This reduction in proteinuria directly correlates with slowed CKD progression 5

Management of Chronic Kidney Disease Stage 3 – Evidence‑Based Recommendations

Blood Pressure Management

SGLT2 Inhibitor Renoprotection

Diabetes Medication Adjustments in CKD Stage 3

Monitoring Frequency for CKD Stage 3